

July 28, 2025

SymBio Pharmaceuticals Limited

Fuminori Yoshida

Representative Director

President and Chief Executive Officer

(Securities Code: 4582)

**SymBio to Present Preclinical Data on Brincidofovir
in Head and Neck Cancer at ESMO 2025 Congress**

SymBio Pharmaceuticals Limited conducted a preclinical study to explore the therapeutic potential of brincidofovir (BCV) in solid tumors and obtained promising findings for its application in head and neck cancer. We are pleased to inform you that these research results have been selected for poster presentation at the European Society for Medical Oncology (ESMO Congress 2025), to be held in Berlin, Germany, from October 17 to 21, 2025.

Tetsu Kamitani, MD, PhD, who will be giving the presentation, states: “The present data suggest the potential of BCV as a novel therapeutic agent in the treatment of head and neck cancer. It holds promise as a new therapeutic option in oncology and is expected to provide hope to many patients suffering from head and neck cancer.”

Summary of the presentation

Title: Preclinical efficacy of brincidofovir (BCV) against head and neck squamous cell carcinoma (HNSCC)

Presenter: Tetsu Kamitani

Presentation Number: 1304P

(Note)

ESMO Congress 2025

ESMO is one of the most authoritative societies in the world, leading the fields of cancer treatment and research. Founded in 1975, it serves as an essential forum where oncology specialists, researchers, medical professionals, and pharmaceutical industry representatives share the latest advancements and research findings in cancer treatment.

Head and Neck Cancer

The term head and neck refers to the region encompassing the face and neck, located between the skull base (the lower part of the head) and the clavicle. This region includes the nose, paranasal sinuses, oral cavities, pharynx, larynx, salivary glands, and thyroid gland. Cancers arising in these areas are collectively referred to as "head and neck cancers." The estimated annual incidence is over 900,000 cases worldwide and approximately 35,000 cases in Japan. Additionally, it is known that Epstein-Barr virus (EBV) and human papillomavirus (HPV) are known to be involved in the carcinogenesis of nasopharyngeal carcinoma and oropharyngeal carcinoma, respectively.